-
Views
-
Cite
Cite
J. HENSEN, O. HADER, V. BAHR, W. OELKERS, Effects of Incremental Infusions of Arginine Vasopressin on Adrenocorticotropin and Cortisol Secretion in Man, The Journal of Clinical Endocrinology & Metabolism, Volume 66, Issue 4, 1 April 1988, Pages 668–671, https://doi.org/10.1210/jcem-66-4-668
Close - Share Icon Share
Arginine vasopressin (AVP) regulates ACTH release under certain conditions, and exogenously administered AVP is used clinically to stimulate ACTH secretion. We attempted to determine at what plasma concentration AVP can stimulate ACTH release. Six normal men were given infusions of AVP (Ferring) or vehicle between 1600 and 1700 h on five occasions: 1) saline (30 mL/h); 2) 10 ng AVP/min; 3) 30 ng AVP/min; 4) 100 ng AVP/min; and 5) 300 ng AVP/min. Plasma AVP, ACTH, and cortisol concentrations were measured every 10 min during the infusions.
Basal plasma AVP levels were less than 1 ng/L (<0.92 pmol/ L). The lowest AVP dose raised plasma AVP into the range found in fluid-deprived subjects (7–8 ng/L; 6.5–7.3 pmol/L), but had no effect on plasma ACTH concentrations. AVP in a dose of 30 ng/min also had no effect. The 100 ng AVP/min dose raised plasma AVP concentrations to 51.4–65.5 ng/L (46–60pmol/L). This increase led to a transient insignificant increase in plasma ACTH from 13.9 ± 1.2 (±SEM) ng/L (3.1 ± 0.3 pmol/ L) to 20.0 ± 1.4 ng/L (4.4 ± 0.3 pmol/L), while plasma cortisol rose significantly from 146 ± 10 to 209 ± 19nmol/L (P < 0.01) after 60 min of infusion. The 300 ng AVP/min dose raised plasma AVP levels to about 260 ng/L (239 pmol/L); the maximal plasma ACTH andcortisol levels were 39.5 ± 5.0 ngpmol/L). This increase led to a transient insignificant increase in plasma ACTH from 13.9 ± 1.2 (±SEM) ng/L (3.1 ± 0.3 pmol/ L) to 20.0 ± 1.4 ng/L (4.4 ± 0.3 pmol/L), whileplasma cortisol rose significantly from 146 ± 10 to 209 ± 19 nmol/L(P < 0.01) after 60 min of infusion. The 300 ng AVP/min dose raisedplasma AVP levels to about 260 ng/L (239 pmol/L); the maximal plasma ACTH andcortisol levels were 39.5 ± 5.0 ng/L (8.7 ± 1.1 pmol/L; P < 0.01) and 348 nmol/L (P < 0.01), respectively. Thus, peripheral plasma AVP levels have to be raised high above the physiological range before ACTH release is stimulated. We conclude that any AVP reaching the adenohypophysis through the peripheral circulation is of much less importance for the regulation of ACTH secretion than is AVP derived from the pituitary portal circulation.
